Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients

ConclusionsA majority of IBC patients in our study presented with node-positive disease, and for those presenting with cN2-3 disease, more extensive axillary surgery is potentially associated with improved survival. For cN0 patients, however, more extensive axillary surgery was not associated with a survival benefit, suggesting an opportunity for more personalized care.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research

Related Links:

CONCLUSION: HER2 FISH ratio showed prognostic value among patients with HER2+ non-IBC but not HER2+ IBC treated with neoadjuvant chemotherapy. This disparity may be due to the underlying aggressive nature of IBC. IMPLICATIONS FOR PRACTICE: The findings of this study indicate that the HER2 to fluorescence in situ hybridization ratio as a continuous variable has promise as a predictor of pathologic complete response to neoadjuvant chemotherapy in patients with HER2-positive (HER2+) noninflammatory breast cancer (non-IBC) regardless of the results on HER2 immunohistochemical testing. In the future, some patients with HER...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
AbstractPurpose of ReviewInflammatory breast cancer (IBC) is an aggressive type of breast cancer with poor prognosis. Treatment for non-metastatic disease is neoadjuvant chemotherapy followed by mastectomy and radiation. IBC diagnosis is primarily a clinical diagnosis, which can lead to misdiagnosis and delayed management. In addition, there are no molecular criteria for diagnosis or therapeutic regimens developed specifically for IBC. We aimed to discuss recent developments in IBC, including diagnosis, molecular mechanisms, and treatment.Recent FindingsRecently, the Union for International Cancer Control (UICC) and the Am...
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research
AbstractPurposeTo analyze the influence of hormone receptors (HR) and Human Epidermal growth factor Receptor-2 (HER2)-based molecular subtypes in stage III inflammatory breast cancer (IBC) on tumor characteristics, treatment, pathologic response to neoadjuvant chemotherapy (NACT), and overall survival (OS).MethodsPatients with stage III IBC, diagnosed in the Netherlands between 2006 and 2015, were classified into four breast cancer subtypes: HR+/HER2 − , HR+/HER2+ , HR−/HER2+ , and HR−/HER2− . Patient-, tumor- and treatment-related characteristics were compared. In case o...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Publication date: May 2019Source: European Journal of Surgical Oncology, Volume 45, Issue 5Author(s): Siun Walsh, Michaela Higgins, Emma Stanley, Maurice Stokes, Malcolm Kell, Mitchel Barry
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Condition:   Breast Cancer Interventions:   Drug: Nivolumab 360 mg+ paclitaxel 80 mg/m2;   Drug: Doxorubicin 60 mg/m2+Cyclophosphamide 600 mg/m2;   Drug: Nivolumab 360 mg+ Docetaxel* 75 mg/m2 +Trastuzumab 8 mg/kg +Pertuzumab 840 mg;   Drug: Doxorubicin 60 mg/m2 +Cyclophosphamide 600 mg/m2 Sponsor:   New York University School of Medicine Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This patient presents with stage IV, cT4dN3cM1 oligometastatic inflammatory breast cancer (IBC) (1). The initial treatment would be neoadjuvant chemotherapy (NAC). In the absence of progression with NAC, we would recommend mastectomy with axillary lymph node dissection and postmastectomy radiation therapy (PMRT). Given IBC's penchant for locoregional recurrence and progression to carcinoma en cuirasse, an aggressive approach to PMRT is warranted, despite the presence of initial limited metastatic disease.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Inflammatory Breast Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pathology | Study